Racial Disparities Skew Most Type 2 Diabetes Clinical Trials
A meta-analysis of 82 published randomized clinical trials (RCTs) of treatments for patients with type 2 diabetes showed that non-White participants appear to be underrepresented relative to their disease burden, while White participants appear over-represented. The greatest disparities in diversity were found in industry-funded trials, which constituted most of the trials examined.
@sachin The burden of type 2 diabetes is disproportionately higher in non-White than White racial and ethnic groups. RCTs produce the most reliable evidence on efficacy and safety of various interventions, and they inform society recommendations and public health prevention strategies. Underrepresentation of non-White individuals in RCTs could limit the generalizability and uptake of the trial findings among groups with the highest disease burden.